In a report published Wednesday, Piper Jaffray analyst William R. Quirk upgraded the rating on Becton, Dickinson and Co. BDX from Neutral to Overweight, and raised the price target from $91.00 to $117.00.
In the report, Piper Jaffray noted, “Observations from multiple diagnostic conferences all suggest significant interest in microbiology investment. This interest spans track systems (Kiestra), new identification technologies (Maldi/BioTyper) and Molecular (gram +/- assays). When considering AST (antimicrobial susceptibility testing) recall from Siemens, we believe BD's microbiology business is poised to accelerate its performance over the next several years. Combined with a delayed JNJ/Ypsomed pen needle launch and incremental European safety adoption, we believe numbers for BD will continue to climb and accordingly are raising our rating to Overweight with a $117 price target, up from $91.”
Becton, Dickinson and Co. closed on Tuesday at $100.80.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in